Lifeboat Foundation

Watch Video

In this lesson, Chris Wark shares a sneak peek into the diet, mind-set, and daily practices that helped him beat stage three-C colon cancer at the age of 26. Through the details of his amazing healing journey, you’ll discover the alternatives to traditional chemotherapy that helped him heal cancer painlessly and while maintaining his vigor and zest for life.

You’ll learn…

Two major U.S. biomedical research funders plan to each put at least $100 million over 4 years toward bringing cutting-edge, gene-based treatments to a part of the world that often struggles to provide access to even basic medicines: sub-Saharan Africa. The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation today announced the unusual collaboration to launch clinical trials for gene-based cures for HIV and sickle cell disease within the region in the coming decade.

The ambitious goal is to steer clear of expensive, logistically impractical strategies that require stem cell transplantation, and instead develop simpler, affordable ways of delivering genes or gene-editing drugs that can cure these diseases. “Yes, this is audacious,” NIH Director Francis Collins said during a press teleconference this morning on the project. “But if we don’t put our best minds, resources, and visions together right now, we would not live up to our mandate to bring the best science to those who are suffering.”

After decades of work and setbacks, the traditional gene therapy approach of delivering DNA into the body to replace a defective gene or boost a protein’s production is now reaching the clinic for several diseases, including inherited blindness, neuromuscular disease, and leukemia. Animal studies and some clinical trials have suggested that two diseases prevalent in Africa, HIV and sickle cell disease, can be treated by gene therapies or newer genome-editing tools such as CRISPR.

Gene-Edited Bulls

Although GMO wheat, corn, and other crops are frequently used in the US, scientists and farmers have begun shifting their focus to a far more accurate, cheaper, and potentially acceptable way of tinkering with the genome: genetic editing.

We’ve spilled plenty of ink on the merits of CRISPR and older-generation genetic editors such as TALEN. Rather than blindly sticking additional genes into a genome, these are guided approaches that surgically snip out or insert additional genetic material, and as such, are far more precise and predictable. Rather than inserting alien genes into our foods, scientists can now cut out genes detrimental to crop growth, or mimic mutations that provide advantages—a sort of “gene therapy” for food, but for enhancement rather than treatment.

Hayley Harrison sent me this video taken-filmed by Andrés Grases and posted it to Youtube… I know for a certainty that Gene therapy will not increase Life span into 125 or beyond years due to the Animal Eukartyotic cell of the earth having a plague that infects all cells into mutation and early cell death.

This year I had the privilege to record in full Liz Parrish talk delivered at RAADfest 2019 (Revolution Against Aging and Death Festival 2019), which took place in Las Vegas, NV from 3 to 6 of October.

Continue reading “Liz Parrish conference at RAADfest 2019 (05-Oct-2019)” »

Say this about the kinds of molecular mayhem that we know underlie aging: Mechanisms like whether the ends of chromosomes fray (bad) and whether genes’ on-off status breaks down (really bad) at least sound like plausible ways to impair vital organs, from skin to brains and hearts, and produce the whole sorry mess known as aging.

On Wednesday, scientists reported a driver of aging that, in contrast, even the lead researcher diplomatically calls “counterintuitive”: neuronal activity. Aging, of course, affects the brain. But the brain seems to affect aging, too, they found: In creatures from worms to mice to people, high levels of neuronal firing spell a shorter life span. Lower levels — naturally, or due to drugs that dampen neurons’ activity — increase longevity.

The discovery⁴ was so surprising that it’s taken two years to be published (in Nature) because of how much additional data the outside scientists reviewing the study requested. Geneticist Bruce Yankner of Harvard Medical School, who led the research, understood their skepticism. “If you say you have a cat in your backyard, people believe you,” he said. “If you say you have a zebra, they want more evidence.”

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Huda Suliman of Icaria Life Sciences discussed her company’s role in the rejuvenation biotechnology ecosystem, including small molecule drug discovery and drug screening along with how her company deals with irreproducibility in the scientific literature. She explained how species differences are an issue, and she explained the differences between aging-focused and traditional medical research.

Drug company says it will seek permission in the US to start marketing the potentially ‘life-changing’ new drug.

Plemper says additional toxicity tests in animals have not thrown up any red flags, and the first trials of EIDD-2801 in humans are likely to start next spring. Pavia says the new drug could eventually be used in combination with other drugs to stave off resistance, a strategy already in use for HIV and hepatitis B treatments.

People not washing their hands after going to the toilet, rather than undercooked meat, is behind the spread of a key strain of E. coli.

Experts looked at thousands of blood, faecal and food samples.

They found human-to-human transmission was responsible — “faecal particles from one person reaching the mouth of another”.